Losartan versus atenolol on 24-hour ambulatory blood pressure. A LIFE substudy

Lia E. Bang*, Niels Wiinberg, Kristian Wachtell, John Larsen, Michael H. Olsen, Christian Tuxen, Per R. Hildebrandt, Hans Ibsen

*Corresponding author af dette arbejde

    Publikation: Bidrag til tidsskriftArtikelForskningpeer review


    Objective. The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study showed that losartan-based treatment reduced risk of the composite endpoint of cardiovascular death, stroke and myocardial infarction compared with atenolol-based treatment in patients with hypertension and left ventricular hypertrophy with similar office blood pressure (BP) reduction. Our aim was to investigate the effect of losartan- and atenolol-based treatment on 24-h ambulatory BP and heart rate (HR) in LIFE. Methods. In 110 patients, 24-h ambulatory BP and heart rate were recorded at baseline and 1 year after randomization. Results. Ambulatory BP was comparably reduced throughout the 24-h period after 1 year of losartan- vs atenolol-based antihypertensive treatment. Office and ambulatory BP were comparably reduced in the follow-up period. Early morning surge in BP was similar between groups. Non-dipping status was more frequent in the losartan group (p = 0.01). From baseline to Year 1 the 24-h HR profile for the losartan group was unchanged, but, as expected, there was a significant decrease in daytime HR in the atenolol group, which was not as large during early night-time. Conclusion: There were no differences in 24-h BP burden and HR that could explain the difference in outcome in favor of losartan vs atenolol in the LIFE study.

    Sider (fra-til)392-397
    Antal sider6
    TidsskriftBlood Pressure
    Udgave nummer6
    StatusUdgivet - 14 dec. 2007


    Udforsk hvilke forskningsemner 'Losartan versus atenolol on 24-hour ambulatory blood pressure. A LIFE substudy' indeholder.